13D Filings
ESSA PHARMA, INC.
Amendment
Ownership

5.10%

Total Shares

2,262,026

Issuer CIK

1633932

CUSIP

29668H708

Event Date

Apr 22, 2025

Accepted

Apr 23, 2025, 09:45 PM

Reporting Persons (6)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
SOLEUS CAPITAL MASTER FUND, L.P.
Partnership
5.10%2,262,02602,262,026
SOLEUS CAPITAL, LLC
Other
5.10%2,262,02602,262,026
SOLEUS CAPITAL GROUP, LLC
Other
5.10%2,262,02602,262,026
SOLEUS CAPITAL MANAGEMENT, L.P.
Partnership
5.10%2,262,02602,262,026
SOLEUS GP, LLC
Other
5.10%2,262,02602,262,026
GUY LEVY
Individual
5.10%2,262,02602,262,026
Disclosure Items (3)

Security Title

Common Stock

Issuer Name

ESSA PHARMA, INC.

Issuer Address

Suite 720, 999 West Broadway, British Columbia, A1, V5Z 1K5

Master Fund has entered into cash settled swap transactions with respect to which it receives payments calculated by reference to the rate of return on Common Stock in exchange for payments by Master Fund to the swap counterparty equal to a fixed or floating interest rate on the notional amount of the swap. As of the date of this Amendment, these swaps reflect economic exposure to an aggregate of 4,025,351 shares of Common Stock. Master Fund does not obtain any beneficial ownership of the Common Stock (including the power to vote or direct the voting, or dispose or direct the disposition, of the shares of Common Stock that are subject to the swaps) or any right to obtain the Common Stock in connection with these swap transactions, and may enter into additional swap transactions or terminate existing swap transactions at any time. As a result, the Reporting Persons disclaim beneficial ownership of the shares of Common Stock that are subject to the swaps transactions. Other than the Joint Filing Agreement attached as Exhibit 1 to the original Schedule 13D, or as otherwise described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons and between such persons and any person with respect to any securities of the Issuer.

1. Joint Filing Agreement, dated April 15, 2025, among the Reporting Persons. (#) 2. Letter dated April 15, 2025 from Soleus Capital Management, L.P. to the Board of Directors of the Issuer. (#) # Previously filed as an exhibit to the original Schedule 13D filed by the Reporting Persons on April 15, 2025.